Clinical Trials Browser

Phase 3 × Has results × Aromatase Inhibitors × Clear all

NCT02003209 2025-08-08

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Phase 3 Completed

315 enrolled 11 charts

Breast Neoplasms

NCT01160211 2025-03-07

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Phase 3 Completed

369 enrolled 19 charts

Breast Neoplasms